Search Within

Joshua Chaim

Formats
  1. Journal Article (24)
  2. Meeting Abstract (14)
  3. Book Section (2)
Groups
  1. Body Imaging Service (40)
  2. Radiology, Department of (40)
  3. Department of Medicine (27)
  4. Epidemiology and Biostatistics (26)
  5. Solid Tumor Oncology Division (25)
  6. Genitourinary Oncology Service (24)

More Groups

People
  1. Martin Voss (17)
  2. Robert Motzer (17)
  3. Chung-Han Lee (14)
  4. Darren Feldman (13)
  5. Maria Carlo (12)
  6. Hebert Vargas Alvarez (10)

More People

Years
  1. 2024 (4)
  2. 2022 (5)
  3. 2021 (2)
  4. 2020 (4)
  5. 2019 (6)
  6. 2018 (4)

More Years

Publications
  1. Journal of Clinical Oncology (14)
  2. Radiology (3)
  3. Atlas of Genitourinary Oncological Imaging (2)
  4. Clinical Genitourinary Cancer (2)
  5. Journal of Digital Imaging (2)
  6. Abdominal Radiology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. Springer (5)
  3. Elsevier Inc. (3)
  4. Radiological Society of North America, Inc. (3)
  5. Wiley Blackwell (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncologic outcomes after localized prostate cancer treatment: Associations with pretreatment prostate magnetic resonance imaging findings
    Journal Article

    Wibmer, A. G.; Chaim, J.; Lakhman, Y.; Lefkowitz, R. A.; Nincevic, J.; Nikolovski, I.; Sala, E.; Gonen, M.; Carlsson, S. V.; Fine, S. W.; more...
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Journal Article

    Feldman, D. R.; Ged, Y.; Lee, C. H.; Knezevic, A.; Molina, A. M.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Murray, S.; Tickoo, S. K.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Cancer susceptibility mutations in patients with urothelial malignancies
    Journal Article

    Carlo, M. I.; Ravichandran, V.; Srinavasan, P.; Bandlamudi, C.; Kemel, Y.; Ceyhan-Birsoy, O.; Mukherjee, S.; Mandelker, D.; Chaim, J.; Knezevic, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Meeting Abstract

    Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (10) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts)
    Meeting Abstract

    Ged, Y.; Chaim, J.; Knezevic, A.; Carlo, M. I.; Foster, A.; Feldman, D. R.; Teo, M. Y.; Riaz, N.; Lee, C. H.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Journal Article

    Shah, A. Y.; Kotecha, R. R.; Lemke, E. A.; Chandramohan, A.; Chaim, J. L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save